Management of OAB in Female Patients .

Elsayed Abdelhalim Elsayed

Status: Completed

Conditions: Overactive Bladder

Treatments: Drug: Solfenacin; Drug: Tadalafil 5mg; Drug: Mirabegron

Study type: Interventional

Funder types: Other

Identifiers

NCT06184334

OAB

Details and patient eligibility

About

The objective of this study is to compare the effectiveness of mirabegron, solifenacin, tadalafil (5mg), and their combination in relieving symptoms of overactive bladder (OAB) in a double-blinded prospective randomized placebo-controlled trial.

Enrollment: 300 patients

Sex: Female

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Women from 18 to 65 years of age with LUTs due to OAB

Exclusion criteria

• Severe cardiovascular disorders. \

  • Severe neurogenic dysfunction.
  • Drug administration which interfere with bladder function .
  • Abnormal bleeding profile.
  • A verified urinary tract infection as determined by urinalysis and/or urine culture during screening

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

300 participants in 3 patient groups

Group A : patients will receive mirabegron

Active Comparator group

Description:

patients will receive mirabegron

Treatment:

Drug: Mirabegron

Group B: patients will receive tadalafil 5mg

Active Comparator group

Description:

patients will receive tadalafil 5mg

Treatment:

Drug: Tadalafil 5mg

Group C: patients will receive solfenacin

Active Comparator group

Description:

patients will receive solfenacin

Treatment:

Drug: Solfenacin